Title
Author
DOI
Article Type
Special Issue
Volume
Issue
Archive
- 2026/Volume 47
- 2025/Volume 46
- 2024/Volume 45
- 2023/Volume 44
- 2022/Volume 43
- 2021/Volume 42
- 2020/Volume 41
- 2019/Volume 40
- 2018/Volume 39
- 2017/Volume 38
- 2016/Volume 37
- 2015/Volume 36
- 2014/Volume 35
- 2013/Volume 34
- 2012/Volume 33
- 2011/Volume 32
- 2011/Volume 31
- 2009/Volume 30
- 2008/Volume 29
- 2007/Volume 28
- 2006/Volume 27
- 2005/Volume 26
- 2004/Volume 25
- 2003/Volume 24
- 2002/Volume 23
- 2001/Volume 22
- 2000/Volume 21
Molecular Characterization in Endometrial Cancer: Progress and Prospects
Deadline for manuscript submissions: 31 December 2022
Print Special Issue Flyer (19)Special Issue Editor
Guest Editor
Andrea Giannini, MD, PhDE-MailWebsite
Department of Medical and Surgical Sciences and Translational Medicine, Sapienza University, Rome, Italy
Interests: Gynecological Tumors; Surgical and Invasive Medical Procedures; Gynecologic Surgery; Women's Health; Obstetrics and Gynecology; Gynecologic Cancers; Oncology
Special Issue Information
Dear Colleagues,
Endometrial carcinoma (EC) is the most common gynecological malignant disease in high income countries. This tumor is increasingly characterized by molecular pattern for prognosis and selection of treatment, drastically changing the treatment options and response rate for advanced and recurrent endometrial cancer and adding new information to the conventional morphologic features. In view of the important prognostic and therapeutic implications, the 2020 ESGO/ESTRO/ESP guidelines for the EC management defined new prognostic risk groups, integrating molecular markers.
Since the great importance given to this new approach, the aim of this special issue is to focus our research on progress and new frontiers on this topic in the precision medicine era, to improve the management and outcomes of EC patients, considering comorbidities and clinical aspects too. Is the validation of a prognostic model possible?
Andrea Giannini, MD, PhD
Gueat Editor
Keywords
Endometrial Cancer (EC); Molecular Biomarkers; Immune Checkpoint Inhibitor; Precision Medicine
Manuscript Submission Information
Manuscripts should be submitted online by submit system. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Original articles, case reports or comprehensive reviews are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website. Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. European Journal of Gynaecological Oncology is an international peer-reviewed open access journal published by MRE Press. Please visit the Instructions for Authors page before submitting a manuscript.The Article Processing Charge (APC) for publication in this open access journal is $1500. We normally offer a discount greater than 30% to all contributors invited by the Editor-in-Chief, Guest Editor (GE) and Editorial board member. Submitted papers should be well formatted and use good English.
Share This Special Issue
Published Papers (1 papers)
Molecular markers and endometrial cancer
Molecular markers and endometrial cancer
DOI: 10.22514/ejgo.2022.051
(This article belongs to the Special Issue Molecular Characterization in Endometrial Cancer: Progress and Prospects )
Abstracted / indexed in
Web of Science (WOS) (On Hold)
Journal Citation Reports/Science Edition
Google Scholar
JournalSeek